Abstracts tagged "inflammatory arthritis and innate immunity"

Abstract Number: 1296 • 2013 ACR/ARHP Annual Meeting
Deletion Of RBP-J In a Murine Model Of Inflammatory Arthritis Reveals Pro-Inflammatory Cytokine Expression and Immunophenotypic Differences
Soumya D. Chakravarty¹, Karmen Au², Lionel B. Ivashkiv³ and Xiaoyu Hu⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁴Arthritis Tissue Degeneration Program, Hospital for Special Surgery, New York, NY
Background/Purpose: RBP-J, a DNA-binding protein, serves as the central transcriptional regulator of the Notch signaling pathway. Prior in vitro work has demonstrated that RBP-J plays…
Abstract Number: 1163 • 2013 ACR/ARHP Annual Meeting
The Receptor For Advanced Glycation End Products (RAGE) As a Modulator Of Inflammatory Responses and Its Contribution To Gender-Specific Effects During Arthritis
Timo Wirth¹, Christoph Kessel¹, Philipp Becker², Toni Weinhage³, Nadine Nippe⁴ and Dirk Foell⁵, ¹Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²University of Muenster, Muenster, Germany, ³Pediatric Rheumatology and Immunology, University of Muenster, Münster, Germany, ⁴Department of Dermatology, University of Muenster, Münster, Germany, ⁵Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor expressed on various cells which interacts with a diverse class of ligands,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].